[144] Ormat Technologies, Inc. SEC Filing
Form 144 filed for Ormat Technologies, Inc. (ORA) reports a proposed sale of 535 common shares through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $48,896.33 and approximately 60,723,470 shares outstanding. The filer acquired these shares on 08/18/2025 via Stock Appreciation Rights from the issuer and intends to receive cash on sale. The notice also discloses a recent sale by the same person of 460 shares on 06/27/2025 for gross proceeds of $38,658.40. The signer represents no undisclosed material adverse information and warns that false statements are criminally punishable.
- Detailed compliance with Rule 144 disclosure requirements including broker, quantity, and acquisition method
- Sale size is small relative to total outstanding shares (~60.7 million), indicating limited market impact
- Insider liquidity activity (535 shares to be sold and prior 460-share sale) could indicate personal cash needs, though amounts are small
Insights
TL;DR: Small insider sale via Rule 144 following SAR vesting; de minimis relative to outstanding shares.
The filing documents a planned disposition of 535 shares valued at $48,896.33 to be executed through Morgan Stanley Smith Barney on the NYSE, with the shares acquired the same day by exercise/vesting of Stock Appreciation Rights and to be paid in cash. Given the issuer's ~60.7 million shares outstanding, this sale is immaterial to capitalization and unlikely to affect market dynamics. The filing also notes a prior sale of 460 shares on 06/27/2025 for $38,658.40, indicating recent limited insider liquidity activity rather than systematic disposition.
TL;DR: Procedural compliance with Rule 144 and disclosure norms; no governance red flags in the notice.
The Form 144 provides required details: broker identity, quantity, market value, acquisition date and method (Stock Appreciation Rights), and recent sales history. The signer affirms absence of material nonpublic information and includes the mandatory criminal-statement warning. There is no indication of unexpected executive departure, regulatory issue, or concentrated selling that would raise governance concerns based on the disclosed amounts.